Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China | Zendy

Qianqian Fan | Zendy; WaiKit Ming | Zendy; Wai-ying Yip | Zendy; Joyce H. S. You | Zendy

Open Access

Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China

Author(s) -

Qianqian Fan,

WaiKit Ming,

Wai-ying Yip,

Joyce H. S. You

Publication year - 2018

Publication title -

international journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.278

H-Index - 89

eISSN - 1878-3511

pISSN - 1201-9712

DOI - 10.1016/j.ijid.2018.10.007

Subject(s) - bedaquiline , tuberculosis , regimen , medicine , china , intensive care medicine , mycobacterium tuberculosis , geography , pathology , archaeology

Hong Kong is a high-income city of China with an intermediate tuberculosis (TB) burden, and 1% of TB cases are multidrug-resistant (MDR-TB). The aim of this study was to examine the potential cost-effectiveness of adding bedaquiline or delamanid to the background regimen (BR) for the treatment of MDR-TB in Hong Kong.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research